From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment resistant depression to improve on the risk profile seen today with esketamine

2 hours ago
1 min read

CEO Dirk Beher describes the unmet need in this setting, and compares and contrasts FundaMental's dual-acting profile with esketamine. The company is working on a €43 million series A aimed to get them all the way to a substantial proof of concept inflection point.

https://vimeo.com/1188070963

Recent Posts

See All

From Germany: Most ADCs use microtubule inhibitors or DNA-damaging agents as their payload. Heidelberg Pharma believes a greater diversity is needed and has a unique amanitin payload for its programs

From Germany: The Head of Research at BioMed X, which was founded in Heidelberg but now does science around the globe, highlights a few key research projects

CorTec Neuro's brain-computer interface is designed to both stimulate the brain of those recovering from stroke and do thought based computer control. A patient in Seattle used his mind to play Pong

From Germany: FundaMental Pharma aims to develop a dual-acting NMDA receptor modulator for treatment resistant depression to improve on the risk profile seen today with esketamine

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight